Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18002385 | 0.91 | MAPT (0.46) | POLBMAPTMAOBPLATNR4A2 | |
| SCHEMBL18002480 | 0.81 | SRD5A2 (0.52) | POLBMAPTPPARDPPARAMAOB | |
| SCHEMBL21944881 | 0.81 | PPARD (0.46) | POLBMAPTPPARDPPARAMAOB | |
| SCHEMBL28017853 | 0.79 | NR4A2 (0.63) | POLBMAPTMAOBNR4A2 | |
| SCHEMBL18002479 | 0.79 | MAOB (0.49) | PPARAMAOBNR4A2 | |
| SCHEMBL6690271 | 0.77 | RAB9A (0.54) | POLBMAPTPPARDPPARAMAOB | |
| SCHEMBL2241857 | 0.77 | PRF1 (0.55) | MAPT | |
| Bromide SCHEMBL28540140 | 0.75 | MAOB (0.58) | PPARDPPARAMAOBNR4A2FFAR1 | |
| SCHEMBL1134037 | 0.73 | ERCC5 (0.49) | MAPT | |
| SCHEMBL15009636 | 0.73 | APP (0.50) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | POLB 539/4885MAPT 2196/4885PPARD 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.